Related Experiment Video
Updated: Jun 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
"Complicated" right bundle branch block
1Consulting, 2261 Constance Drive, Oakville, Ontario L6J 5L8, Canada. rossmackenzieconsulting@msn.com
Insights
Isolated right bundle branch block is usually benign. However, complex patterns on an electrocardiogram may indicate hidden heart disease impacting long-term survival.
Area of Science:
- Cardiology
- Electrophysiology
- Diagnostic Medicine
Background:
- Right bundle branch block (RBBB) is often considered a benign electrocardiographic finding.
- Its significance can change when associated with other cardiac abnormalities.
Observation:
- The study focuses on "electrocardiographically-complicated" RBBB.
- This specific pattern warrants further medical evaluation.
Findings:
- "Electrocardiographically-complicated" RBBB suggests the potential for underlying, undiagnosed structural heart disease.
- This finding is crucial for assessing patient prognosis.
Implications:
- Medical directors should be alerted to occult heart disease in patients with complicated RBBB.
- Early detection of associated heart conditions can improve long-term survival outcomes.
Abstract:
Isolated right bundle branch block is generally regarded as a benign finding in the absence of underlying structural heart disease. The presence of "electrocardiographically-complicated" right bundle branch block should alert the medical director to occult heart disease, which might impact on long-term survival.
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure Drugs: β-Blockers

